MedTrace Logo

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

NCT03733587 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-05-14

No results posted yet for this study

Summary

This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.

Conditions

Interventions

DRUG

GX-I7

GX-I7 25mg/ml/vial

DRUG

Cyclophosphamide

Cyclophosphamide 500mg/vial

Sponsors & Collaborators

  • Genexine, Inc.

    lead INDUSTRY

Principal Investigators

  • Minkyu Heo · Genexine_clinical team

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-17
Primary Completion
2020-04-02
Completion
2020-05-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03733587 on ClinicalTrials.gov